CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Purpose: This study will evaluate the safety of CHOP plus Alemtuzumab in patients with T/NK
cell lymphomas and CD-20 negative large B-cell lymphomas who have not had previous
treatments. The biological response of lymphoma cells and the immune system to this drug
combination will also be measured in patients before, during, and after therapy
administration.